SOURCE: Nanosphere

August 22, 2013 08:00 ET

Nanosphere to Present Data on the Verigene® System at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

NORTHBROOK, IL--(Marketwired - Aug 22, 2013) - Nanosphere, Inc. (NASDAQ: NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will present data from eight studies at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, in Denver, CO. Six studies will illustrate the accuracy and reliability of Nanosphere's Verigene® System in detecting bloodstream infections. A seventh study compares the accuracy of the Verigene System versus the BioFire FilmArray for rapid identification of gram-positive bacteria in blood cultures; and an eighth compares the accuracy of the Verigene System with Meridian BioScience's Illumigene and Quidel's AmpliVue for rapid identification of C. difficile in stool.

"We are pleased with the growing body of clinical evidence that demonstrates the sensitivity and specificity of the Verigene System in rapidly and accurately detecting infectious pathogens and drug resistance markers," said Michael McGarrity, Nanosphere's president and chief executive officer. "Early and accurate diagnosis, particularly for critical bloodstream and gastrointestinal infections, is vital to healthcare providers for determining the most appropriate course of treatment for their patients."

Nanosphere data to be presented at ICAAC:

1. Poster D-106: "Nanosphere Verigene v BioFire FilmArray for Rapid ID of Gram-Positive Cocci in Blood Cultures," Dr. C.J. Sailey et al.; Arkansas Children's Hospital and the University of Arkansas, Ark. [Tuesday, September 10th, 12 - 1 pm]

2. Poster D-107: "Clinical Performance Characteristics of the Nanosphere Verigene Gram Positive Blood Culture Test," T. Wakefield et al.; The Johns Hopkins Clinical Microbiology Laboratory and the Department of Pathology of the Johns Hopkins University School of Medicine, Md. [Tuesday, September 10th, 12 - 1 pm]

3. Poster D-108: "Evaluation of the Verigene BC-GP Test for Identification of Gram-Positive Organisms from Positive Versatrek Blood Culture (BC) bottles," Dr. E. L. Palavecino et al.; Wake Forest Baptist Medical Center, N.C. [Tuesday, September 10th, 12 - 1 pm]

4. Poster D-109: "Impact of Rapid Molecular Identification of Gram-Positive Cocci and Resistance Determinants in Positive Blood Cultures on Targeted Antibiotic Therapy of Bacteremia Due to Gram-Positive Cocci," Dr. R.M. Martinez et al.; University of Washington, Wash. [Tuesday, September 10th, 12 - 1 pm]

5. Poster D-110: "Evaluation of Verigene Gram-Positive and Gram-Negative Blood Culture Assays Performance for Bacteremic Patients," Ph. M. Dodémont et al.; Hôpital Erasme, Brussels. [Tuesday, September 10th, 12 - 1 pm]

6. Poster D-111: "Evaluation of Microarray Based Rapid Diagnostic Test for Direct Identification of Gram-Negative Bacteria and Resistance Genes From Positive Blood Cultures," Dr. M. Tojo et al.; Disease Control and Prevention Center, Tokyo, Japan. [Tuesday, September 10th, 12 - 1 pm]

7. Poster D-112: "Evaluation of a Microarray-Based Sample-to-Result Assay for the Rapid Detection of Gram-Negative Bacteria and Antibiotic Resistance Markers Directly from Positive Blood Culture Bottles," Dr. R. A. Winegar et al.; MRIGlobal, Fla. [Tuesday, September 10th, 12 - 1 pm]

8. Poster C-1147a: "Correlation of Illumigene, Verigene, and AmpliVue for Rapid Identification of C. difficile in Stool," Dr. C.J. Sailey et al.; Arkansas Children's Hospital and the University of Arkansas, Ark. [Thursday, September 12th, 11am - 1 pm]

About the Verigene® System

The Verigene® System uses core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by mapping the genome of a particular bacterium. Currently, Verigene assays target infections of the bloodstream, respiratory tract and gastrointestinal tract. The System also offers additional capabilities in cancer, cardiovascular disease and autoimmune disease. The information gathered from Verigene enables clinicians to identify diseases earlier and make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, reduced spread of antibiotic resistance and saved lives.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, and enable optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene® System, allows clinicians to rapidly identify the most complex, costly and deadly infectious diseases through simple-to-use multiplexed diagnostic testing. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

Contact Information